International Journal of Hematology

DOI: 10.1007/s12185-016-1951-0 Pages: 373-379

Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes

1. Hôpital Robert-Debré, AP-HP et Université Paris 7-Paris Diderot, Service d’Hémato-immunologie

2. Hôpital Saint-Louis, AP-HP et Université Paris 7-Paris Diderot, Service d’Hématologie Greffe

Correspondence to:
Jean-Hugues Dalle



Inherited bone marrow failure (IBMF) syndromes are a heterogeneous group of rare hematological disorders characterized by the impairment of hematopoiesis, which harbor specific clinical presentations and pathogenic mechanisms. Some of these syndromes may progress through clonal evolution, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Most prominent are failures of DNA repair such as Fanconi Anemia and much rarer failure of ribosomal apparatus, e.g., Diamond Blackfan Anemia or of telomere elongation such as dyskeratosis congenita. In these congenital disorders, hematopoietic stem cell transplantation (HSCT) is often a consideration. However, HSCT will not correct the underlying disease and possible co-existing extra-medullary (multi)-organ defects, but will improve BMF. Indications as well as transplantation characteristics are most of the time controversial in this setting because of the rarity of reported cases. The present paper proposes a short overview of current practices.

This article is freely available, click here to access the full text/PDF

Share the Knowledge